The Dorling Group (also known as the Transplant Inflammation & Repair Group) is led by Professor Anthony Dorling.
A major research theme of the group is vascular inflammation, focusing on cellular and molecular mechanisms involved in immune responses relevant to transplants. One strand involves coagulation proteases, such as thrombin, and the critical roles they play in inflammation, including atherosclerosis. The same pathways are involved in arteriosclerosis and tissue fibrosis.
Clinically, we focus on studying T and B cells in HLA-sensitised patients awaiting transplantation or with chronic rejection. They run the large UK RCT OuTSMART, and in 2020 will begin a new MRC-funded phase 2 study to define whether Treg therapy can suppress memory responses to HLA.